Inhalation

Kaival Brands Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Bidi, Tax, Growth, Stick, Inhalation, KAVL, Security (finance), Insurance, Advertising, Patel

GRANT-VALKARIA, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ("Kaival Brands" or the "Company,"), the exclusive U.S. distributor of all products manufactured by Bidi Vapor, LLC ("Bidi Vapor"), on Monday announced its financial results for the fiscal 2024 first quarter ended January 31, 2024 and provided a business update.

Key Points: 
  • GRANT-VALKARIA, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ("Kaival Brands" or the "Company,"), the exclusive U.S. distributor of all products manufactured by Bidi Vapor, LLC ("Bidi Vapor"), on Monday announced its financial results for the fiscal 2024 first quarter ended January 31, 2024 and provided a business update.
  • Reduced net inventories to $2.1 million as of January 31, 2024, down 49.5% from $4.1 million as of October 31, 2023.
  • Terminated service agreement with QuikFillRx (d/b/a Kaival Marketing Services), the third-party service provider responsible for increasing sales of Bidi Sticks, effective February 22, 2024.
  • Revenues: Revenues for the first quarter of fiscal year 2024 were $3.2 million, compared to $2.5 million in the same period of the prior fiscal year.

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, March 25, 2024
Research, Conference, ATS, Actelion, Patent, Intellectual, Patient, Inhalation, Travel, Merck, Sale, American Thoracic Society, Investment, Clinical trial, Merck & Co., Therapy, PAH, Pharmaceutical industry

Cash, cash equivalents and short-term investments totaled $122.4 million as of December 31, 2023, compared to $135.2 million as of September 30, 2023.

Key Points: 
  • Cash, cash equivalents and short-term investments totaled $122.4 million as of December 31, 2023, compared to $135.2 million as of September 30, 2023.
  • The decrease was primarily driven by operational costs for the three-month period ended December 31, 2023.
  • Net loss: Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.
  • Net loss included stock-based compensation expense of $11.9 million and $5.5 million for the years ended December 31, 2023 and December 31, 2022, respectively.

Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing

Retrieved on: 
Wednesday, March 20, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Volunteering, RSV, ARI, Aris, Human, Inflammation, SARS, Patient, Inhalation, Antibody, Serum, Injection, Vaccine

The study upends prevailing thinking about inhaled antibody delivery by demonstrating that antibodies maintain their activity following nebulization and can be dosed uniformly to all parts of the respiratory tract, including the deep lung.

Key Points: 
  • The study upends prevailing thinking about inhaled antibody delivery by demonstrating that antibodies maintain their activity following nebulization and can be dosed uniformly to all parts of the respiratory tract, including the deep lung.
  • It also shows that inhaled antibodies can achieve concentrations throughout the respiratory tract greatly exceeding the levels required to neutralize most acute respiratory viruses.
  • The greater convenience, dose savings and reduced burden on healthcare infrastructure supports initiating inhaled antibody treatment at the earliest time possible.
  • The much greater antibody concentrations achieved in the respiratory tract with inhalation suggests the potential for even greater therapeutic effect.

Cotchett, Pitre & McCarthy Files Lawsuit on Behalf of Residents of Maywood, CA, for Exposure to Cancer Causing Ethylene Oxide

Retrieved on: 
Monday, March 18, 2024
Professional Services, Legal, Environment, Bone marrow, Public health, Inhalation, National Cancer Institute, Breast, Ethylene oxide, Cancer, Leukemia, Ethylene, Aplastic anemia, Complaint, Atmosphere, Breast cancer, Partner, Superior court, Family, Stomach, Spice, Los Angeles Times, Lymphoma, Stomach cancer, Oil

Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.

Key Points: 
  • Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.
  • Ethylene Oxide is used to sterilize medical equipment and spices but, during the process, some of the Ethylene Oxide escapes the facility into the surrounding air.
  • Ethylene Oxide is odorless and colorless, so nearby Maywood residents never knew it was in the air surrounding their homes.
  • According to the National Cancer Institute, and other protective health agencies around the world, Ethylene Oxide is associated with breast cancer, stomach cancer, lymphoma, and leukemia.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

New Research Shows a Surge in Popularity of Shisha Across the Globe as Demand for Cleaner Experiences Grows

Retrieved on: 
Monday, March 18, 2024
Other Retail, Tobacco, Consumer Electronics, Technology, Online Retail, Consumer, Other Consumer, Retail, Temperature, Growth, Environment, Inhalation, Research, Corporate Affairs, Carbon, Smoking, Water, AIR

This surge is predicted to drive the industry towards 24.6m shisha users in 2024, an increase of 18.27%, and 32.3 million shisha users by 2026, reflecting an increase of 55.28%.

Key Points: 
  • This surge is predicted to drive the industry towards 24.6m shisha users in 2024, an increase of 18.27%, and 32.3 million shisha users by 2026, reflecting an increase of 55.28%.
  • The global shisha market, currently valued at $19 billion, is projected to expand to $22 billion by 2026.
  • This surge in demand for shisha is fuelled by a growing appetite for more innovative and cleaner products.
  • “As shisha market leaders, AIR Global is dedicated to redefining the shisha experience which led to the launch of OOKA – the world's first charcoal-free pod-based shisha device.

Azuca Takes the Fast Lane with Infusions in the Hemp Cannabinoid Market Through Strategic Collaboration with Open Book Extracts

Retrieved on: 
Thursday, April 4, 2024
RTD, Absorption, CGMP, Inhalation, Titan Mare Explorer, Infusion, OBX, NSF, Drink, B2B, Chocolate, THC

NEW YORK, April 4, 2024 /PRNewswire/ -- Azuca, a trailblazer in advanced infusions within the regulated cannabis market, today announced a strategic collaboration with leading cannabinoid ingredient and product manufacturer Open Book Extracts (OBX) for the burgeoning hemp market, inclusive of federally-compliant, hemp-derived delta-9 THC.

Key Points: 
  • This collaboration harnesses Azuca's innovative TiME INFUSION® process and ACTiVATOR® product line with OBX's expertise in cannabinoid ingredients, product development, and finished goods manufacturing.
  • Positioned as a "fast track" solution, Azuca and OBX will offer brands and manufacturers a streamlined pathway from concept to market, significantly reducing the time it takes to reach consumers.
  • "At Azuca, we are dedicated to pushing the boundaries of innovation to deliver efficient, reliable, and delicious cannabis experiences for consumers.
  • "Open Book Extracts is committed to making products that work for brands that care," shares Nicole Brown, OBX Chief Innovation Officer.

Puffshot E-Cigarettes Triumph with Prestigious 2024 Design Awards, Redefining Vaping Experience

Retrieved on: 
Tuesday, April 2, 2024
Temperature, Taste, Consciousness, Multiple, Inhalation, Child, Cart, Safety, Tobacco

HOUSTON, April 2, 2024 /PRNewswire/ -- Puffshot, a leading e-cigarette brand, has proudly announced its latest achievement in the international design arena, having recently won the renowned French Design Gold Award and the American Good Design Award for 2024.

Key Points: 
  • HOUSTON, April 2, 2024 /PRNewswire/ -- Puffshot, a leading e-cigarette brand, has proudly announced its latest achievement in the international design arena, having recently won the renowned French Design Gold Award and the American Good Design Award for 2024.
  • These prestigious recognitions highlight Puffshot's commitment to innovation and excellence in design, underscoring the brand's significant impact within the global design community.
  • With a "Collect and Deliver" new design and 5x reinforced vaping experience, it sets new standards in taste preference consistency.
  • Today, Puffshot, with its unique charm and innovative spirit, is redefining the vaping experience and leading a new trend in the e-cigarette industry.

CPSC Warns Consumers to Immediately Stop Using Elide Fire Extinguishing Balls Due to Failure to Extinguish Fires and Risk of Serious Injury or Death

Retrieved on: 
Thursday, March 28, 2024
UL, Burns, CPSC, Risk, Inhalation, Smoke, Death, Fire, Injury, Fireworks

These products can fail to extinguish a fire, which could lead to serious injury and death.

Key Points: 
  • These products can fail to extinguish a fire, which could lead to serious injury and death.
  • Specifically, the products can fail to effectively disperse fire retardant chemicals and fail to extinguish a fire.
  • Elide Fire USA has not agreed to recall these fire extinguishing balls or offer a remedy to consumers.
  • Elide Fire USA sells three models of the fire extinguishing balls to consumers on elidefireus.com.

Joint Statement from the Co-Chairs of the Special Advisory Committee on the Epidemic of Opioid Overdoses - Latest National Data on Substance-Related Harms

Retrieved on: 
Wednesday, March 27, 2024
Consciousness, Risk, Opioid, COVID-19, Patient, Benzodiazepine, Ageing, Inhalation, Public, Naloxone, Portrait, Epidemic, Male, Special Advisory Committee, Xylazine, Government, Fentanyl, Pharmaceutical industry

These numbers are the largest observed since data collection  began in 2016, signifying the ongoing worsening of this urgent public health crisis.

Key Points: 
  • These numbers are the largest observed since data collection  began in 2016, signifying the ongoing worsening of this urgent public health crisis.
  • These latest data show that in Canada between January and September 2023, there were 5,975 apparent opioid-related deaths and 4,646 hospitalizations for opioid-related poisonings.
  • New data from emergency departments (ED) show that during the same period, there were 21,708 reported opioid poisoning ED visits, which is 80 per day.
  • While it may take time to see results, everything we do to help combat this crisis and save lives is critical.